Warfarin Drug Interactions
Warfarin has one of the longest lists of drug interactions of any medication. Its narrow therapeutic index makes even modest changes in metabolism or protein binding clinically dangerous.
## Why Warfarin Is High Risk
Warfarin has a narrow therapeutic index (target INR 2.0-3.0 for most indications), a long half-life (20-60 hours), and is metabolized by multiple CYP enzymes. It exists as R- and S-enantiomers; S-warfarin is 3-5 times more potent and primarily cleared by CYP2C9, while R-warfarin is metabolized by CYP1A2, CYP3A4, and CYP2C19.
## Mechanisms of Interaction
### CYP Enzyme Inhibition/Induction
The most dangerous interactions involve CYP2C9, which governs S-warfarin clearance:
- **Fluconazole, amiodarone, metronidazole** — inhibit CYP2C9, increasing S-warfarin levels and INR
- **Rifampin** — induces CYP2C9, CYP3A4, and CYP1A2 simultaneously, potentially halving warfarin's effect within a week
### Protein Binding Displacement
Warfarin is 99% protein-bound. While displacement alone rarely causes sustained INR elevation, it transiently increases free warfarin and may be relevant when combined with metabolic inhibition.
### Vitamin K Interference
- **Antibiotics** (fluoroquinolones, cephalosporins) may suppress gut flora that produce vitamin K, amplifying warfarin's effect
- **Dietary vitamin K** — sudden increases (leafy greens) reduce INR; decreases (illness-related poor intake) raise INR
### Pharmacodynamic Interactions
- **Aspirin, NSAIDs** — impair platelet function and damage GI mucosa, increasing bleeding risk independent of INR changes
- **SSRIs** — inhibit platelet serotonin uptake, increasing bleeding risk additively
## Most Dangerous Combinations
| Interacting Drug | Mechanism | Effect on INR |
|-----------------|-----------|---------------|
| Fluconazole | CYP2C9 inhibition | Marked increase |
| Amiodarone | CYP2C9 + CYP3A4 inhibition | Increase (may persist months) |
| Rifampin | Pan-CYP induction | Dramatic decrease |
| Metronidazole | CYP2C9 inhibition | Moderate increase |
| TMP-SMX | CYP2C9 inhibition + folate effect | Significant increase |
| Phenytoin | Complex bidirectional | Variable |
Amiodarone deserves special attention: its half-life exceeds 40 days, so the interaction develops slowly over weeks and persists for months after discontinuation.
## Management Strategies
1. **Check INR within 3-5 days** of adding or stopping any interacting drug
2. **Preemptively reduce warfarin dose** by 25-50% when starting amiodarone or fluconazole
3. **Avoid NSAIDs** entirely when possible; use acetaminophen for pain (at doses below 2 g/day)
4. **Maintain consistent vitamin K intake** rather than avoiding greens entirely
5. **Consider DOAC alternatives** (apixaban, rivarelor) for patients with frequent co-medication changes
## Key Takeaways
- S-warfarin is the potent enantiomer cleared by CYP2C9; inhibitors of this enzyme are the highest risk
- Amiodarone's ultra-long half-life means the interaction develops and resolves over weeks to months
- Antibiotics affect warfarin through both CYP inhibition and vitamin K depletion
- NSAIDs increase bleeding risk pharmacodynamically even without changing INR
- INR should be rechecked 3-5 days after any medication change